Lundbeck
HLUN-B.CO
$4.64
Share price
-0.85%
Change (1 day)
-8.12%
Change (1 year)
Categories
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.
Revenue for Lundbeck (HLUN-B.CO)
Revenue in 2023 (TTM): $2.89 B
According to Lundbeck 's latest financial reports the company's current revenue (TTM) is $2.89 B. In 2022 the company made a revenue of $2.58 B an increase over the years 2021 revenue that were of $2.55 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lundbeck from 2009 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $2.89 B | 12.23% |
| 2022 | $2.58 B | 1.24% |
| 2021 | $2.55 B | -7.03% |
| 2020 | $2.74 B | 5.51% |
| 2019 | $2.60 B | -7.85% |
| 2018 | $2.82 B | 5.99% |
| 2017 | $2.66 B | 14.81% |
| 2016 | $2.31 B | 7.19% |
| 2015 | $2.16 B | -8.56% |
| 2014 | $2.36 B | -12.76% |
| 2013 | $2.71 B | 4.77% |
| 2012 | $2.58 B | -12.76% |
| 2011 | $2.96 B | 13.7% |
| 2010 | $2.60 B | 0.37% |
| 2009 | $2.59 B |